KR20130029284A - Composition of healthy foods for treatment of dementia - Google Patents
Composition of healthy foods for treatment of dementia Download PDFInfo
- Publication number
- KR20130029284A KR20130029284A KR1020110092638A KR20110092638A KR20130029284A KR 20130029284 A KR20130029284 A KR 20130029284A KR 1020110092638 A KR1020110092638 A KR 1020110092638A KR 20110092638 A KR20110092638 A KR 20110092638A KR 20130029284 A KR20130029284 A KR 20130029284A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- pine
- health food
- dementia
- food composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 206010012289 Dementia Diseases 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title description 5
- 235000001497 healthy food Nutrition 0.000 title description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 58
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 58
- 241000018646 Pinus brutia Species 0.000 claims abstract description 58
- 239000000284 extract Substances 0.000 claims abstract description 37
- 235000013402 health food Nutrition 0.000 claims abstract description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003960 organic solvent Substances 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims abstract description 10
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000013361 beverage Nutrition 0.000 claims abstract description 7
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000007902 hard capsule Substances 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 5
- 239000007901 soft capsule Substances 0.000 claims abstract description 5
- 235000020357 syrup Nutrition 0.000 claims abstract description 5
- 239000006188 syrup Substances 0.000 claims abstract description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 3
- MILWSGRFEGYSGM-UHFFFAOYSA-N propane-1,2-diol;propane-1,2,3-triol Chemical compound CC(O)CO.OCC(O)CO MILWSGRFEGYSGM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 240000006079 Schisandra chinensis Species 0.000 claims description 12
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 230000006872 improvement Effects 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 241000121220 Tricholoma matsutake Species 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 7
- 230000002490 cerebral effect Effects 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 210000003456 pulmonary alveoli Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000032683 aging Effects 0.000 description 12
- 229930014626 natural product Natural products 0.000 description 12
- 230000035882 stress Effects 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 230000003938 response to stress Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000014571 nuts Nutrition 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 206010027175 memory impairment Diseases 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 208000034656 Contusions Diseases 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000013016 learning Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 240000007263 Pinus koraiensis Species 0.000 description 3
- 235000011615 Pinus koraiensis Nutrition 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- -1 flavorings Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009863 impact test Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 208000010233 scurvy Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007103 stamina Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000007440 Agaricus campestris Species 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000937413 Axia Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 208000013017 Child Nutrition disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 244000252132 Pleurotus eryngii Species 0.000 description 1
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039759 Scrotal swelling Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 241000543375 Sideroxylon Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000393 hypersympathetic effect Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020094 liqueur Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- JOLPFRQHFARWCF-UHFFFAOYSA-N propane-1,2,3-triol;prop-1-ene Chemical group CC=C.OCC(O)CO JOLPFRQHFARWCF-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000020097 white wine Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Abstract
Description
본 발명은 치매 개선용 건강식품 조성물에 관한 것으로, 더욱 상세하게는 소나무 잔뿌리, 송이, 잣, 천마 및 오미자로 이루어진 군으로부터 선택되는 2종 이상 혼합물의 추출물을 함유하는 치매 개선용 건강식품 조성물에 관한 것이다. The present invention relates to a health food composition for improving dementia, and more particularly, to a health food composition for improving dementia containing extracts of two or more kinds of mixtures selected from the group consisting of pine twigs, pine, pine, cheonma and schisandra chinensis. will be.
최근 사회구조가 급변하면서, 사회 생활을 통해 스트레스성 질환 및 노화의 가속화 등으로 노화 및 노화와 관련된 다양한 질병 혹은 질환으로 인하여, 많은 의료비용이 발생하고, 이러한 의료비 증가가 사회적 비용 증가로 연결되고 있다. 노화와 관련된 질환 중에서도 특히 노인성 뇌질환(치매)은 최근 들어, 노인 질환 중에서도 대표적인 질환으로 손꼽히고 있다. 또한, 학업에 시달리는 청소년, 각종 취업으로 인한 입사시험, 사회 참여의 다양화를 위해 각종 자격 시험을 준비하는 사회 참여 인구의 증가, 평생 교육의 확대로 인한 중장년층의 교육 활동 등이 확대되면서, 뇌를 많이 사용하는 인구가 폭발적으로 증가하고 있고, 이로 인하여, 노화의 진행에 따른 치매에 대한 관심도 매우 증가하게 되었다. 이를 해결하기 위하여, 다양한 건강기능식품, 특히, 가바(GABA, Gamma amino butyric acid)나, 포스파티딜세린(Phosphatidylserine) 등의 건강식품 소재가 개발되었으며, 두뇌의 기능을 조절하는 약물로서, 지각능력을 증진시키고, 두뇌의 노화를 늦추는 효과가 있는 것으로 알려진 피라세탐(Piracetam)이라는 의약품도 시판되고 있다.Recently, as the social structure changes rapidly, many medical expenses are incurred due to various diseases or diseases related to aging and aging due to stress diseases and acceleration of aging through social life, and this increase in medical expenses is leading to an increase in social costs. . Aging-related brain disease (dementia), among diseases related to aging, has recently been regarded as a representative disease among elderly diseases. In addition, the number of youths suffering from academic studies, entrance examinations due to various employment, social participation population preparing for various qualification tests for diversification of social participation, and education activities of middle-aged and seniors due to expansion of lifelong education have been expanded. There is an explosive increase in the number of people using it, which has led to a great deal of interest in dementia as the aging progresses. In order to solve this problem, various health functional foods, especially health food materials such as GABA (Gamma amino butyric acid) and phosphatidylserine (Phosphatidylserine), have been developed. Piracetam, a drug known to be effective in slowing the aging of the brain, is also available.
스트레스는 모든 병의 근원으로 인체의 부조화와 순환장애 등을 유발하여 질병의 원인으로 작용한다. 인체가 스트레스를 받게 되면 자신을 보호하기 위해 시상하부-뇌하수체-부신계(Hypothalamus-Pituitary-Adrenal, HPA axis) 및 부신수질 및 교감신경계의 항진으로 에피네프린(epinephrine) 및 노어에피네프린(norepinephrine)의 분비를 증강시키며 시상하부에서 코티코트로핀 분비인자(corticotropin releasing factor) 분비 증가, 뇌하수체 전엽에서 부신피질자극호르몬(adrenocorticotropic hormone, ACTH) 분비증가, 부신수질에서 코티코스테론(corticosterone), 알도스테론(aldosterone) 등의 분비를 증가시켜 스트레스 반응을 나타낸다. 스트레스 반응에는 혈압상승, 심박동수 증가, 행동변화, 위장관으로부터 골격근으로의 혈액 이동, 비장무게의 감소, 백혈구수 감소로 인한 면역력 감소 등이 있다. 스트레스의 정도가 크고 오랫동안 받게 되거나 우리 인체의 스트레스 반응 시스템에 결함이 있으면 병으로 연결된다. 스트레스 반응을 수행하는 시상하부-뇌하수체-부신계(HPA axia) 및 교감신경의 항진은 심각한 만성질환, 우울증, 신경성 식욕감퇴, 망상-강박장애, 공황장애, 당뇨병, 갑상선기능항진, 중심성 비만, 고혈압, 심장병 같은 질병을 초래한다.Stress is the source of all diseases, causing incongruity and circulatory disorders in the human body, acting as a cause of disease. When the body is under stress, secretion of epinephrine and norepinephrine is achieved by the hypothalamus-pituitary-adrenal (HPA axis) and the adrenal medulla and sympathetic nervous system. Increased corticotropin releasing factor secretion in the hypothalamus, increased adrenocorticotropic hormone (ACTH) secretion in the anterior pituitary gland, corticosterone and aldosterone in the adrenal medulla Increased secretion results in a stress response. Stress responses include increased blood pressure, increased heart rate, behavioral changes, blood flow from the gastrointestinal tract to skeletal muscle, decreased spleen weight, and decreased immunity due to reduced white blood cell count. If the stress is large and long-lasting, or if our body's stress response system is defective, it can lead to illness. Hypothalamic-pituitary-adrenal system (HPA axia) and hypersympathetic nerve conducting stress response can cause severe chronic diseases, depression, anorexia nervosa, reticulism, panic disorder, diabetes mellitus, hyperthyroidism, central obesity, hypertension It causes diseases like heart disease.
소음, 공해, 불안상태나 억울 등 과도한 스트레스는 면역능력에 영향을 미쳐 생체에 저항능력을 억제하여 감염, 자가면역 및 뇌의 퇴행성 질환 등 각종 질병을 일으키는 것으로 알려지면서, 스트레스의 발병기전에 심혈관계, 내분비계와 더불어 면역계의 역할에 연구의 초점이 모아지고 있다. 면역계에서 중요한 역할을 하는 사이토킨(cytokine)이 스트레스 반응을 조절하여 스트레스성 질환을 유발시키는 것으로 알려져 있다. 즉, 시상하부(hypothalamus)와 해마(hippocampus)를 비롯한 중추신경계 내에서 사이토킨의 방출은 국소 염증반응을 일으켜 인체에 매우 해로운 요소로 작용할 수 있다. 장기간의 스트레스에 노출되면 해마 내 신경세포의 소실이 오며 학습과 기억에 심각한 영향을 미친다. 하지만, 스트레스에 의한 사이토킨의 방출과 학습, 기억 소실 및 불안 등의 스트레스 반응과의 관련성에 대한 연구가 진행중이나 아직 그 기전과 역할이 잘 알려져 있진 않고 있다. 유기체가 살아가면서 접하게 되는 환경적인 스트레스를 통제한다는 것이 실제로 불가능하며, 스트레스와 관련된 여러 질환이 급등하는 현실을 감안할 때, 스트레스에 대한 면역계의 반응으로 나타나는 행동증상의 기전을 이해하는 것은 우리가 스트레스에 대처하는데 많은 도움을 줄 것이다. 따라서, 스트레스의 중추성 면역학적 기전을 밝혀 새로운 약물 및 치료방법의 개발에 필요한 이론적인 배경을 제공하는 연구가 절실히 요구되고 있다.Excessive stress, such as noise, pollution, anxiety or depression affects the immune system, inhibits the body's ability to resist and causes various diseases such as infections, autoimmunity, and degenerative diseases of the brain. In addition, research is focused on the role of the immune system as well as the endocrine system. Cytokines, which play an important role in the immune system, are known to control stress response and cause stress disorders. That is, the release of cytokines in the central nervous system, including the hypothalamus and hippocampus, can cause local inflammation and act as a very detrimental factor to the human body. Exposure to prolonged stress can lead to the loss of nerve cells in the hippocampus and seriously affect learning and memory. However, studies on the relationship between the release of cytokines caused by stress and stress responses such as learning, memory loss and anxiety are ongoing, but the mechanisms and roles of these are not well known. It is virtually impossible to control the environmental stresses that an organism encounters in life, and given the reality that stress-related diseases soar, the understanding of the mechanisms of behavioral symptoms in response to the immune system in response to stress is what makes us stressed. It will help you a lot. Therefore, there is an urgent need for researches that reveal the central immunological mechanisms of stress and provide a theoretical background for the development of new drugs and treatments.
치매는 다양한 원인으로 발병할 수 있으나, 알츠하이머성 치매가 노인성 치매 중 가장 많은 부분을 차지하고 있으며 주요 발병요인은 베타아밀로이드(Ab1-42)의 뇌내 축적과 그로 인한 신경 독성이 발병의 매우 중요한 원인으로 알려져 있으며[Selkoe, Annu. Rev. Neurosci., 17, 489-517(1994)], 기타 다른 요인들도 거론되고 있다. 결국, 치매의 근본적인 원인은 노화와 더불어서 발생되는 각종 세포 내 독성에 의한 신경세포의 활성저하 및 사멸에 있다. 그러나 현재까지 알려진 치매 치료제(tacrine, Cognex; Donepezil, Aricept)들은 신경전달 물질인 아세틸콜린(acetylcholine)의 작용을 증진시키는 것들로서 치매의 증상이 어느 정도 완화될 수는 있지만 여러 가지 부작용(간 독성, 구토, 설사 등)이 문제점으로 알려져 있다.Alzheimer's disease can be caused by a variety of causes, but Alzheimer's disease is the most common cause of senile dementia, and the main cause of the disease is the accumulation of beta amyloid (Ab1-42) in the brain and its neurotoxicity. And Selkoe, Annu. Rev. Neurosci., 17, 489-517 (1994)] and other factors. After all, the root cause of dementia is the deactivation and death of neurons by various intracellular toxicity that occurs with aging. However, tacrine, cognex (donepezil, and aricept) known to date are known to enhance the action of acetylcholine, a neurotransmitter, which may alleviate some of the symptoms of dementia. Vomiting, diarrhea, etc.) are known problems.
최근 들어, 기존의 의학을 대체한 천연물 및 기타 요법을 이용한 대체의학이 강조되면서, 천연물을 이용한 천연물 의약품 혹은 건강기능식품에 대한 관심이 높아지고 있다. 실제로 천연물 신약과 천연물 개별인정형 건강식품의 제품 개발이 매우 활발하게 진행되고 있으며, 이에 따라 기존의 의학으로 쉽게 접근하지 못했던 분야에 대한 연구도 활발히 진행되고 있다. 앞서 언급한 바와 같이 사회구조가 급변하면서, 사회 생활을 통해 스트레스성 질환 및 노화의 가속화 등으로 노화 및 노화와 관련된 다양한 질병 혹은 질환을 효율적으로 치료하기 위해, 기존의 방법에 비하여 부작용이 적으면서도 효과는 더욱 뛰어날 것으로 알려진 천연물 의약품 혹은 건강기능식품에 대한 개발이 필요한 시점이며, 또한, 지속적인 연구를 통하여, 이러한 방법의 과학적인 검증과 임상이 필요하다. In recent years, the emphasis on alternative medicine using natural products and other therapies replacing conventional medicine is increasing interest in natural products or health functional foods using natural products. Indeed, the development of products of natural products and natural products individually certified health food is very active, and thus, researches on fields that are not easily accessible with conventional medicine are being actively conducted. As mentioned above, as the social structure changes rapidly, it is effective to treat various diseases or disorders related to aging and aging through the stress of life and accelerated aging through social life, while having fewer side effects than conventional methods. Is the time to develop natural medicines or dietary supplements that are known to be even better, and through ongoing research, scientific validation and clinical testing of these methods are needed.
따라서 본 발명에서의 발명자 등은 우리나라의 전통 한방과 한의학 서적을 참고로 하여 관련 질환에 가장 효과적일 것으로 생각되는 천연물을 스크리닝하여, 천연물의 효과를 직접 검토하고자 하였으며, 이 중에서 치매 개선용 원료를 찾아내고, 치매 개선 효과에 대한 검증을 진행하였다. 이러한 방법을 통하여, 임상적 효능과 전통 한의학이 근거가 되는 효과적인 천연물을 찾아내고, 과학적 근거를 찾아내어, 치매 개선용 건강식품을 개발하여, 다양한 연령층이 포함된 뇌 관련 시장에서의 우수한 효과를 가지는 천연물을 확보하고 이를 통하여 시장 경쟁력을 확보할 것으로 기대된다. Therefore, the inventors of the present invention screened the natural products that are considered to be the most effective for the related diseases with reference to the traditional Chinese medicine and oriental medicine books in Korea, and tried to directly examine the effects of the natural products, among them to find a raw material for improving dementia The dementia improvement effect was verified. Through this method, we find effective natural products based on clinical efficacy and traditional Chinese medicine, find scientific evidence, develop health foods for improving dementia, and have excellent effects in the brain-related market including various age groups. It is expected to secure natural products and thereby secure market competitiveness.
따라서, 본 발명은 폐포를 씻어내어, 뇌에 산소 공급을 원활하게 하고, 뇌혈관을 깨끗하게 청소하며, 뇌혈관의 피를 깨끗이 조혈하기 위한 순환기능을 강화함으로써, 치매 개선용 건강식품 조성물을 제공하는데 그 목적이 있다. Therefore, the present invention is to provide a healthy food composition for improving dementia by washing the alveoli, smoothing the oxygen supply to the brain, cleans the cerebrovascular vessels, and enhances the circulation function to clean the blood of the cerebrovascular vessels, The purpose is.
본 발명의 일 구체예에서, 소나무 잔뿌리, 송이, 잣, 천마 및 오미자로 이루어진 군으로부터 선택되는 2종 이상 혼합물의 추출물을 함유하는 치매 개선용 건강식품 조성물을 제공한다.In one embodiment of the present invention, there is provided a health food composition for improving dementia containing an extract of two or more mixtures selected from the group consisting of pine twigs, pine, pine, cheonma and schizandra.
혼합물의 추출물이 조성물 총 중량에 대하여 각각 0.001~10 중량%의 양으로 함유되고, 혼합물의 조성이 건조중량을 기준으로 하여 소나무 잔뿌리 1 ~ 40 중량%, 잣 1 ~ 40 중량%, 천마 1 ~ 40 중량% 또는 오미자 1 ~ 40 중량%의 양으로 함유된다.The extract of the mixture is contained in an amount of 0.001 to 10% by weight relative to the total weight of the composition, and the composition of the mixture is 1 to 40% by weight of pine twigs, 1 to 40% by weight, pine nuts 1 to 40, based on dry weight. It is contained in an amount of 1% to 40% by weight or Schisandra chinensis.
또한, 상기 건강식품 조성물이 정제, 과립제, 연질캅셀제, 경질캅셀제, 시럽, 음료수, 환(丸), 연조엑스제, 건조엑스제, 중탕액 및 추출중탕액으로 이루어진 군으로부터 선택되는 1종 이상의 제형이다.In addition, the health food composition is one or more formulations selected from the group consisting of tablets, granules, soft capsules, hard capsules, syrups, beverages, pills, soft extracts, dry extracts, water baths and extract baths to be.
본 발명의 일 구체예에서, 상기 추출물이 물, 유기용매 또는 이들의 혼합물로 추출되고, 유기용매가 탄소수 1 내지 4의 알코올성 용매인데, 바람직하게는 메탄올, 에탄올, 프로필 알코올, 부틸알코올, 글리세린 프로필렌글라이콜 및 부틸렌글라이콜로 이루어진 군으로부터 선택되는 1종 이상이다. In one embodiment of the invention, the extract is extracted with water, an organic solvent or a mixture thereof, the organic solvent is an alcoholic solvent having 1 to 4 carbon atoms, preferably methanol, ethanol, propyl alcohol, butyl alcohol, glycerin propylene At least one selected from the group consisting of glycol and butylene glycol.
본 발명에 따른 조성물은 폐포를 씻어내어, 뇌에 산소 공급을 원활하게 하고, 뇌혈관을 깨끗하게 청소하며, 뇌혈관의 피를 깨끗이 조혈하기 위한 순환기능을 강화함으로써, 치매를 개선하는데 효과적이고, 또한, 섭취가 용이하다. 또한, 천연 유래의 추출물을 사용하여 음용시 위험성이 없고, 인체에 안전하며 장기간 복용하여도 부작용이 없다는 장점이 있다. The composition according to the present invention is effective in improving dementia by rinsing alveoli, facilitating oxygen supply to the brain, cleans cerebrovascular vessels, and strengthens circulatory functions to clean the blood of cerebrovascular vessels, , Easy to ingest. In addition, there is no risk when drinking using extracts derived from natural, safe to the human body has the advantage that there is no side effect even when taken for a long time.
본 발명을 더욱 상세히 설명하면 다음과 같다. The present invention is described in more detail as follows.
본 발명의 치매 개선용 건강식품 조성물의 유효성분인 소나무 잔뿌리, 송이, 잣, 천마 또는 오미자는 다음과 같은 특징을 가지고 있다. Pine leaf, pine, pine, cheonma or schisandra chinensis as an active ingredient of the health food composition for improving dementia of the present invention has the following characteristics.
소나무(Pinus densiflora )는 줄기는 높이 35m, 지름 1.8m 정도이며 수피는 붉은빛을 띤 갈색이나 밑부분은 검은 갈색이다. 바늘잎은 2개씩 뭉쳐나고 길이 8~9cm, 너비 1.5mm이다. 2년이 지나면 밑부분의 바늘잎이 떨어진다. 꽃은 5월에 피고 수꽃은 새 가지의 밑부분에 달리며 노란색으로 길이 1cm의 타원형이다. 암꽃은 새 가지의 끝 부분에 달리며 자주색이고 길이 6mm의 달걀 모양이다. 열매는 달걀 모양으로 길이 4.5cm, 지름 3cm이며 열매조각은 70~100개이고 다음해 9~10월에 노란빛을 띤 갈색으로 익는다. Pinus densiflora ) Stem is 35m in height and 1.8m in diameter, and bark is reddish brown but the bottom is black brown. Needle leaves are put together two by 8 ~ 9cm long and 1.5mm wide. After two years, the needle leaves fall down. Flowers bloom in May, and male flowers hang on the bottom of the new branch, yellow, 1cm long, oval. Female flower hangs on the end of new branch and is purple and 6mm long egg shape. Fruits are egg-shaped, 4.5cm long, 3cm in diameter, 70-100 pieces of fruit, and ripen yellowish brown in September-October the following year.
소나무는 노화를 늦추는 작용, 살균작용, 항염증작용, 기침을 멈추게 하는 작용, 영양작용, 경련성 항염증작용, 지혈작용, 담즙분비촉진작용, 장수작용, 항암작용, 혈압낮춤작용, 니코틴배출작용, 혈중콜레스테롤배출, 혈액순환촉진, 고혈압, 감기의 예방, 유행성 뇌막염의 예방, 만성기관지염, 위 및 십이지장궤양, 피로회복, 만성 변비, 이질이 몇 달이 지나도 깨끗이 낫지 않는 증상, 괴혈병, 어린이 영양실조, 노화방지 및 예방, 소아 습진, 소아 기저귀로 인한 피부염, 외상 출혈, 음낭의 습양, 풍치, 중풍에 의한 구안와사, 잇몸 동통, 혀가 뻣뻣한 증세, 두풍, 두통, 대풍나창, 역절풍, 옴, 타박상, 염좌, 피부 가려움증, 옻오른데, 심근경색증, 심장이 약하거나 심장병, 뇌빈혈, 동맥경화, 뇌경색, 변비, 치질, 질염, 알레르기성 비염, 급성 위염, 만성 알코올 중독, 안저 출혈, 구취, 중풍, 스트레스로 오는 모든 증상, 류머티스, 폐결핵, 결막염, 궤양, 구강염, 신경통, 요통, 어깨 결린데, 잇몸 질환, 치조골 질환, 편도선이 부었을 때, 치통, 불면증, 피로 권태, 불로장생, 콜레스테롤 억제, 습진, 타박상, 부종, 높은 곳에서 떨어져 악혈이 심장을 치고 흉격이 답답하고 괴로운 증상, 치풍, 피부병, 거풍, 진정, 지통, 피부미용, 소염, 유정, 치루, 기생충 구제, 귀가 어두운 증상, 충치통, 새살이 돋아나게 함, 심폐를 촉촉하게 함, 소갈증, 귀와 눈을 밝게 함, 신경성 피부염, 소아 대머리, 간허로 눈물이 나는 증상, 소아가 입을 꼭 다물고 벌리지 못할 때, 귀가 멀고 그 증상이 오래된 증상, 부인 백대하, 모발과 눈썹의 탈락, 현기증, 술독, 신경쇠약, 비타민 C 결핍증, 유행성 뇌막염, 유행성 감기의 예방 및 치료, 영양성 수종, 화상, 동상, 풍습창, 모발촉진, 오장 안정, 풍습골통, 장풍하혈, 만성이질, 차멀미, 오랫동안 아물지 않은 옹저, 금창, 풍습성 관절염, 칼 따위에 베일 상처, 소아 두창 침습, 팔다리 동통, 기의 순환 촉진, 근육통, 경락을 통하게 함, 근육 이완, 타박으로 인한 어혈, 오장 육부를 회춘시키는 등의 수많은 효능을 가지고 있다.Pine is slowing aging, bactericidal, anti-inflammatory, cough-stopping, nourishing, convulsive anti-inflammatory, hemostatic, bile secretion promoting, longevity, anticancer, blood pressure lowering, nicotine excretion, Blood cholesterol release, promotion of blood circulation, prevention of high blood pressure, cold, prevention of epidemic meningitis, chronic bronchitis, gastric and duodenal ulcer, fatigue, chronic constipation, dysentery not clear after several months, scurvy, malnutrition in children, Anti-aging and prevention, pediatric eczema, dermatitis caused by pediatric diapers, traumatic bleeding, scrotum's swelling, taste, swelling due to strokes, gum pain, tongue stiffness, gusts, headaches, blisters, backwinds, scabies, bruises, sprains Itching, skin itching, myocardial infarction, weak heart or heart disease, cerebral anemia, arteriosclerosis, cerebral infarction, constipation, hemorrhoids, vaginitis, allergic rhinitis, acute gastritis, chronic alcohol Poisoning, fundus bleeding, bad breath, stroke, all symptoms of stress, rheumatism, pulmonary tuberculosis, conjunctivitis, ulcers, oralitis, neuralgia, back pain, shoulder swelling, gum disease, alveolar bone disease, tonsils swollen, toothache, insomnia, fatigue Boredom, bully, cholesterol suppression, eczema, bruises, swelling, bleeding, heart attack, swelling and heartburn , Symptoms of darkening of the ears, tooth decay, sprouting of new flesh, moisturizing cardiopulmonary, thirst, brightening ears and eyes, neurodermatitis, pediatric baldness, tears in the liver, when the child does not keep his mouth closed Long-term symptoms, gynecological malaise, hair and eyebrow dropout, dizziness, alcohol poisoning, nervous breakdown, vitamin C deficiency, epidemic meningitis, the prevention and treatment of pandemic cold, nutritional number Species, burn, frostbite, customs window, hair promotion, ileum stabilization, customs bone pain, intestinal bleeding, chronic dysentery, teasickness, long-standing onset, gold lance, customary arthritis, veil wounds, pediatric cranial invasion, limb pain, It promotes circulation of the muscles, muscle pain, meridians through, muscle relaxation, bruises caused by blood, rejuvenate the five intestines, etc.
이 중에서 소나무의 뿌리에는 α-피넨 75%, 캄펜, 디펜텐, α-테르피네올, 캠퍼, p-멘탄올이 있고, 맛은 쓰며 성질은 따뜻하고 독이 없다. 오로(五勞)를 보양하고, 타박어혈동통, 근골통, 상손(傷損) 토혈, 충치통을 치료하는 것으로 알려져 있다. Among them, the roots of pine are 75% α-pinene, camphor, dipentene, α-terpineol, camphor, and p-mentanol. The taste is bitter and the nature is warm and nonpoisonous. It is known to nourish Oro and to treat stiff tooth pain, musculoskeletal pain, upper hand pain, and tooth decay.
근골통은 송눈근(송嫩근)을 물로 달여 백주(白酒)와 함께 복용한다. [호남약물지(湖南藥物誌)] 구혈, 타박상으로 인한 토혈에는 마미송근(馬尾松根)의 거친 껍질을 긁어 버리고 약한 불에 쬐어 말려서 검게 볶아서 곱게 가루를 낸 다음 1회 1돈, 하루 2회, 따뜻한 첨주(甛酒)로 복용한다. [강서민간초약험방(江西民間草藥驗方)] 풍치통, 충치통은 마미송묘(馬尾松苗)의 뿌리인 유송근(幼松根) 1냥을 조각으로 썰어서 돼지 정육 4냥과 함께 고아서 취침 직전에 복용한다. [강서민간초약험방(江西民間草藥驗方)](글/ 약초연구가 & 동아대 대체의학 외래교수 전동명)Musculoskeletal pain is taken with Songjugeun (Songjugeun) with white wine (白酒). [Honam Pharm] In the blood of blood and bruises, scrape off the rough skin of mami pine root, dry it on a low heat, stir-fry it, and finely powder it. Take it with warm liqueurs. [Gangseo Minchocho Drugstore] Wind chimney and tooth decay shall be cut into pieces of Yusong-geun roots of Mami-song-myo, cut into pieces, and taken with pork pork meat and 4 minutes before bedtime. . [Gangseo folk herb medicine laboratory] (Written / Herb Researcher & Adjunct Professor of Alternative Medicine, Dong-A University)
송이(Tricholoma nauseosum ( Blytt ) Kytovuori)는 담자균류 주름버섯목 송이과의 식용버섯으로 향이 독특하고 맛이 좋다. Tricholoma nauseosum ( Blytt ) Kytovuori ) is an edible fungus of the genus Cortis fungus , Pleurotus eryngii .
송이는 혈액순환을 촉진하고, 동맥경화, 심장병 등을 예방할 수 있다. 송이에 들어있는 식이섬유는 콜레스테롤과 담즙산에 달라붙어 함께 배설시키기 때문에 피 속의 콜레스테롤 수치를 떨어뜨리며, 혈액순환을 좋게 하여 동맥경화, 심장병, 당뇨병, 고지혈증 등을 예방하게 한다. 송이는 편도선, 유선염, 탈하증에 효능이 있고, 식욕증진에도 도움이 된다. 송이는 단백질과 비타민이 풍부하여 편도선, 유선염, 탈하증에도 효과가 좋다. 이는 위와 장의 기능을 돕고 식욕을 증진시키고, 설사를 멎게 한다. 또한, 혈액순환을 촉진하여 손발이 저리고 힘이 없거나 무릎이 시릴 때 쓰면 좋다.The cluster may promote blood circulation and prevent arteriosclerosis and heart disease. The dietary fiber in the cluster is attached to cholesterol and bile acids, which are excreted together to reduce blood cholesterol levels and improve blood circulation to prevent atherosclerosis, heart disease, diabetes, and hyperlipidemia. Matsutake is effective for tonsils, mastitis, and dehydration, and also helps to increase appetite. Clusters are rich in protein and vitamins, and are good for tonsils, mastitis, and dehydration. This helps the stomach and intestines function, promotes appetite and diarrhea. In addition, it promotes blood circulation and can be used when hands and feet are numb and have no power or knee pain.
송이는 소화를 도와 비만개선에 도움이 된다. 송이는 전분과 단백질의 소화효소가 들어있어 송이버섯을 곁들인 음식은 소화가 잘 되므로 몸에 열이 많거나 비만인 사람에게 매우 좋다.The cluster helps digestion and improves obesity. The pine mushroom contains digestive enzymes of starch and protein, so the foods with pine mushrooms are well digested, so it is very good for people with high fever or obesity.
송이는 항암효능이 있어 암을 예방한다. 송이에는 암세포를 죽이는 '단독 단백질'이 있는데, 이는 현재까지 알려진 버섯 중 항암효과가 가장 높고 사람의 마음을 안정시키고, 염증을 치유하여 종양을 억제시킨다. Matsutake has anti-cancer effects and prevents cancer. In clusters, there is a 'single protein' that kills cancer cells, which has the highest anti-cancer effect among mushrooms known to date, stabilizes the human heart, cures inflammation, and suppresses tumors.
송이버섯의 주요성분 중 유리 지방산에는 불포화지방산 함유량이 지방산의 82.6~86.7% 범위로 다른 식품에 비해 매우 높게 존재하고 있어 건강식품으로서 각광을 받고 있다. 또한, 무기질 함량은 일반 버섯류에 비하여 타 버섯류와 비교가 되지 않을 만큼 다량 함유되어 있다. 그중에서도 일반적인 버섯의 대표적인 무기질 칼륨은 느타리의 10배, 양송이의 약 40배 정도, 목이버섯의 약 3배 정도 다량 함유되어 있었고, 철분 또한 타 버섯류와 10배 정도로 현격한 차이를 보인다.Among the main components of Matsutake mushroom, free fatty acids have 82.6 ~ 86.7% of fatty acid, which is very high compared to other foods, making it a health food. In addition, the inorganic content is contained in a large amount compared to other mushrooms in comparison with other mushrooms. Among them, the representative mineral potassium of common mushrooms contained 10 times of oysters, about 40 times of mushrooms, and about 3 times of thirsty mushrooms, and iron also showed a tenfold difference from other mushrooms.
잣(Pinus koraiensis Zieb et Eucc)은 소나무과에 속하는 상록교목으로 한국송 또는 한국잣나무의 열매를 말한다. 잎은 솔잎과 비슷하나 좀 더 푸르고 굵다. 보통 소나무는 두 잎의 소나무를 뜻하지만, 잣나무는 솔잎 모양의 잎은 한 군데서 다섯 잎 씩 나오기 때문에 잣나무라고도 한단. 약용으로 정평있는 잣은 해송자(海松子)라 부르고 일명 잣나무(五葉松), 송자(松子), 백자(柏子)라 부르기도 한다. Pinus koraiensis Zieb meat Eucc ) is an evergreen tree belonging to the pine family and refers to the fruit of Korean pine or Korean pine. The leaves are similar to pine needles but greener and thicker. Normally pine means two-leaf pine, but pine tree is also known as pine tree because pine needle-shaped leaves come out in five places. Medicinal pine nuts are called Haesongja (海松 子), also known as pine tree (五 葉松), songza (松子), and white porcelain (柏 子).
잣은 잣나무 이외의 다른 소나무와 마찬가지로 솔방울 속에서 형성되는데 지름 6~10cm, 길이 9~15cm 정도의 솔방울 속에 평균 100알 정도 결실된다. 잣은 칼로리가 높을 뿐 아니라 비타민 B군이 풍부하며 호도나 땅콩보다 철분이 많이 들어 있어 빈혈에도 효과적이다. 잣에는 불포화지방산의 함량이 높고 또한 아미노산의 조성도 우수하다. Like pines other than pine trees, pine nuts are formed in pine cones. On average, about 100 grains are deleted in pine cones of 6 ~ 10cm in diameter and 9 ~ 15cm in length. Pine nuts are not only high in calories, but also rich in B vitamins and contain more iron than hodo or peanuts, which are effective against anemia. Pine nuts have high content of unsaturated fatty acids and excellent amino acid composition.
잣은 올레산, 리놀레산, 리놀렌산 등 불포화 지방산이 많아 피부탄력, 혈압저하 피부를 윤택하게 하고 혈압을 내리게 하며, 스태미나에 도움을 주는 성분으로 알려져 있다. 이 밖에도, 니아신, 나트륨, 단백질, 당질, 레티놀, 베타카로틴, 비타민 A, B, C, E군, 식이섬유, 아연, 엽산, 인, 지질, 철분, 칼륨, 칼슘 등으로 구성 돼 있다.Pine nuts are known to be rich in unsaturated fatty acids such as oleic acid, linoleic acid, and linolenic acid, which make skin elasticity, lower blood pressure, make skin smooth, lower blood pressure, and help stamina. In addition, it is composed of niacin, sodium, protein, sugar, retinol, beta-carotene, vitamin A, B, C, E group, dietary fiber, zinc, folic acid, phosphorus, lipid, iron, potassium, calcium and the like.
천마(Gastrodia elata)는 우리나라 각처의 깊은 산에서 자라는 다년생 초본이다. 생육환경은 습기가 많은 돌 틈과 음지 혹은 반그늘에 참나무류가 쓰러져 썩은 곳에서 자란다. 키는 60~90㎝이고, 잎은 없으며, 생선 비늘과 같은 모양을 한 것이 짧게 있고, 황갈색의 줄기가 올라간다. 뿌리는 길이가 10~18㎝, 지름 3.5㎝로 긴 타원형으로 가로로 뻗는다. 꽃은 황갈색이며 길이는 10~30㎝로 줄기에 붙어 층층이 많은 꽃이 달린다. 열매는 9~10월경에 달리고, 종자는 먼지처럼 작은 것들이 검은 씨방 안에 많이 들어 있다. Gastrodia elata ) is a perennial herb that grows in deep mountains all over Korea. The growing environment grows in decaying oaks in damp stone cracks and shade or half shades. The height is 60 ~ 90㎝, there is no leaf, and the shape of fish scale is short, and the yellowish brown stem is raised. Roots are 10 ~ 18㎝ long and 3.5㎝ in diameter, extending in a long oval. The flower is yellowish brown with the length of 10 ~ 30㎝ attached to the stem. Fruits run from September to October, and seeds are dusty and small in the black ovary.
천마는 고혈압 · 뇌졸중 · 불면증 · 경기 · 두통 · 현기증 · 중풍 · 신경성 질환의 예방과 치료제로 이용하며 당뇨병 등의 성인병과 간 기능 촉진, 피로 · 스트레스 해소 등에도 효능이 있다. 또한, 학습능력과 기억력의 증가에도 효과가 있어서 총명탕의 주재료로 사용되기도 합니다. 천마의 임상적 효능으로는 주로 고혈압, 두통, 마비, 신경성 질환, 당뇨병 등의 성인병과 스트레스, 피로 등의 증상에 효과가 있는 것으로 보고되고 있다. 천마에 있어서 이러한 효능의 기원은 대부분이 천마에 포함되어있는 항산화 물질과 관련되어 있는 것으로 추정됩니다. 일반성분 중에서 조단백질의 함량이 5.4%, 조회분 2.6%, 조지방 3.6%, 조섬유 3.3%, 수분 8.1%이었으며, 전당이 77%로 가장 높았다. 천마는 타작물에 비하여 단백질 함량이 높고, 불포화지방산으로 구성되어 있으며, 천마를 산삼에 비유한다면 일반 마는 도라지에 비할 정도로 그 생김새와 부르는 이름은 비슷할지 몰라도 그 효능에는 차이가 크다. 천마는 다른 식품에 비해 칼슘, 마그네슘, 칼륨 등의 함량이 높은 것으로 알려져 있으며, 최근 여성의 골다공증 치료, 체액의 산성화 방지, 학습능력의 증진 및 혈중 콜레스테롤 함량의 감소에 대한 효과가 인정되는 등 중요한 건강식품으로도 자리를 잡아가고 있는 식물이다.Chunma is used as a preventive and therapeutic agent for hypertension, stroke, insomnia, sports, headache, dizziness, paralysis and neurological diseases. It also has effects on promoting adult disease and liver function such as diabetes, relieving fatigue and stress. It is also effective in increasing learning and memory, and is often used as the main ingredient of Chongmyeongtang. The clinical efficacy of Chunma is reported to be mainly effective in the symptoms of hypertension, headache, paralysis, neurological diseases, diabetes and other diseases, such as stress, fatigue. The origin of this effect in scorpions is presumably related to the antioxidants contained in scorpions. Crude protein content was 5.4%, crude ash 2.6%, crude fat 3.6%, crude fiber 3.3%, moisture 8.1%, and starch was the highest with 77%. Chunma has higher protein content than other crops and is composed of unsaturated fatty acids. If Chunma is compared to wild ginseng, its appearance and calling name may be similar to that of bellflower, but its efficacy is large. Chunma is known to have higher levels of calcium, magnesium, and potassium than other foods, and has recently been recognized for its effectiveness in treating osteoporosis, preventing acidification of body fluids, improving learning ability, and reducing blood cholesterol. It is a plant that is taking its place as a food.
오미자(Schisandra chinensis ( Turcz .) Baill )는 해발이 200~1,600m에 걸쳐 분포하며 지리산, 속리산, 태백산에서 많이 자라는 덩굴성 낙엽 활엽수이다. 키는 6~9m이고, 잎은 길이가 7~10㎝, 폭이 3~5㎝로 뒷면 맥 위에 털이 있고 가장자리에 작은 치아 상의 톱니가 있으며 넓은 타원형으로 어긋난다. 꽃은 약간 붉은빛이 도는 황백색이며 지름이 약 1.5㎝로 3~5송이가 새로 나온 짧은 가지의 잎겨드랑이에 한 송이씩 핀다. 열매는 신맛이 강하고 8~9월에 홍색으로 익으며 길이는 0.6~1.2㎝이고 여러 개가 포도 송이 모양으로 밑으로 처져 달린다. Schisandra chinensis ( Turcz .) Baill ) Is a deciduous deciduous tree that grows in 200 ~ 1,600m above sea level and grows a lot in Jirisan, Sokri and Taebaeksan. The height is 6 ~ 9m, the leaves are 7 ~ 10㎝ long, 3 ~ 5㎝ wide, hairy on the back vein, small tooth teeth on the edge, and wide oval. The flower is slightly reddish yellowish white, about 1.5㎝ in diameter, and blooms one by one on the leaf axilla of 3 ~ 5 new branches. Fruits are sour and strong in red in August ~ September, 0.6 ~ 1.2㎝ in length, and several hang down under grape clusters.
오미자는 해소, 천식에 유효하며 땀을 거두며 진액을 생성시켜 소갈증에 유효하다. 유정(遺精), 유뇨(遺尿), 소변 자주 보는 증상, 오래된 이질, 설사, 가슴이 뛰고 잠을 이루지 못하면서 꿈이 많은 증상에 쓰인다. 기억력 감퇴, 집중력 감소에 효과가 있다. Schisandra chinensis is effective for relieving and asthma, sweating and producing essence, which is effective for small thirst. Oil well (遺精), urination (遺尿), frequent urinating symptoms, dysentery, diarrhea, heart beats and sleep can not be used to dream a lot of symptoms. It is effective in reducing memory and concentration.
약리작용으로 대뇌피질 흥분작용, 혈압 강하작용, 거담, 진해 작용, 호흡 흥분 작용, 강심작용, 당 대사 촉진과 당분해작용, 세포 면역 기능 증강작용, 자궁 흥분 작용, 담즙 분비 촉진 작용, 위액 분비 조절 작용, 항균작용이 보고되고 있다. 또한, 심혈관 계통에 있어 생리적 기능을 조절하고 피의 순환장애를 개선시키며, 중추신경계통의 반응성을 높여 뇌기능을 튼튼하게 하고 정신기능을 안정시켜 치매를 예방할 뿐만 아니라 사고력과 집중력이 필요한 수험생에게도 좋다. Pharmacological action: cerebral cortical excitability, blood pressure lowering, expectoration, antitussive action, respiratory excitability, cardiac action, glucose metabolism and glycolysis, cellular immune function enhancement, uterine excitability, bile secretion, gastric secretion control Action, antibacterial activity has been reported. In addition, it regulates the physiological function in the cardiovascular system, improves blood circulation disorders, increases the responsiveness of the central nervous system, strengthens the brain function and stabilizes the mental function to prevent dementia, and is also good for examinees who need thinking and concentration.
한의학적으로도 오미자는 폐를 돕는 효능이 뛰어난데, 만성기관지확장증 환자의 기침과 천식에 매우 잘 듣고, 공기가 탁한 환경에서 종사하는 사람들의 기침, 가래 증상에 효과적이다. 아이가 기침을 자주 할 때 오미자 우린 물을 꾸준히 먹이면 효험이 있다. 이밖에 혈당치를 떨어뜨려 당뇨병 환자의 갈증 해소에도 도움이 된다. 특히 항 피로 효과가 뛰어나서 건강한 사람도 오미자를 먹으면 약 30분이 지나 정신적 및 육체적 활동력이 높아지고 피로를 덜 느끼게 되는데 이 효과는 3~4시간 계속된다. 감기에 걸렷을때 오미자를 설탕에 담아 숙성시킨 후 그 농축액을 먹으면 감기예방, 면역력 증강에 도움이 되며, 체력을 비축시키는 가을 보약의 효과까지 기대할 수 있다.In Chinese medicine, Schisandra chinensis is effective in helping lungs. It is very effective for coughing and asthma in patients with chronic bronchiectasis, and it is effective for coughing and sputum in people who work in an airy environment. When a child coughs frequently, Schisandra we have a lot of benefits if you continue to feed the water. In addition, blood sugar levels are also helpful for quenching thirst in diabetics. In particular, because of its excellent anti-fatigue effect, healthy people eat Schizandra in about 30 minutes, which increases their mental and physical activity and makes them feel less tired. This effect lasts 3 to 4 hours. When you catch a cold, Schisandra chinensis marinated in sugar and eating the concentrate can help prevent colds and boost immunity, and you can expect the effects of autumn remedies to stock up your stamina.
상술한 소나무 잔뿌리, 송이, 잣, 천마, 오미자 등으로 이루어진 군으로부터 선택된 이종 이상의 한방재료의 혼합물의 추출물은 전체 조성물에 대하여 0.001 내지 10 중량부로 포함될 수 있다. 상기 추출물이 0.001 중량부 미만으로 포함되는 경우, 치매 개선 효과가 미미할 수 있으며, 10 중량부를 초과하여 포함되는 경우에는 제형의 안정성이 저하될 수 있으며, 건강식품 등으로 제조시 맛과 향이 좋지 않을 수 있다. Extract of a mixture of at least two kinds of herbal materials selected from the group consisting of the above pine twigs, pine, pine, scorpion, schizandra, etc. may be included in an amount of 0.001 to 10 parts by weight based on the total composition. When the extract is included in less than 0.001 parts by weight, dementia improvement effect may be insignificant, when included in more than 10 parts by weight may reduce the stability of the formulation, may not be good taste and aroma when prepared as health food have.
상술한 소나무 잔뿌리, 송이, 잣, 천마 및 오미자로 이루어진 군으로부터 선택되는 2종 이상 혼합물의 추출물은 조성물 총 중량에 대하여 0.001~10 중량%의 양으로 함유되는데, 상기 추출물이 0.001 중량% 미만으로 함유되는 경우, 치매 개선용 효과가 미미할 수 있고, 10 중량%를 초과하여 함유되는 경우에는 제형의 안정성이 저하될 수 있으며, 건강식품 등으로 제조시 맛과 향이 좋지 않을 수 있다.Extracts of two or more mixtures selected from the group consisting of pine twigs, pine, pine, cheonma and schizandrae are contained in an amount of 0.001 to 10% by weight, based on the total weight of the composition, containing less than 0.001% by weight of the extract. If it is, the effect for improving dementia may be insignificant, and if it is contained in an amount of more than 10% by weight, the stability of the formulation may be lowered, and taste and aroma may not be good when prepared as a health food.
상기 혼합물의 추출물은 추출용매로서 메탄올, 에탄올 등의 친수성 유기 용매, 또는 친수성 유기용매 및 물의 혼합 용액을 첨가하여 일정 시간 침적시키면서 소정의 시간 간격으로 교반한 후 얻어진 용액을 여과하여 회수하는 통상의 천연물 추출방법에 따라 얻을 수 있다. 바람직한 추출용매로는 탄소수 1 내지 4인 알코올성 용매, 예컨대 메탄올, 에탄올, 프로필 알코올, 부틸알코올, 글리세린 프로필렌글라이콜 및 부틸렌글라이콜, 물 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매가 사용될 수 있으며, 천연물 재료에 가해지는 추출용매의 양은 천연물 재료 전체 부피 대비 1 내지 50 배 정도가 될 수 있다.The extract of the mixture is a natural natural product that is recovered by filtering a solution obtained by adding a hydrophilic organic solvent such as methanol, ethanol or the like, or a mixture of a hydrophilic organic solvent and water and stirring at predetermined time intervals while depositing for a predetermined time. It can be obtained according to the extraction method. Preferred extraction solvents include alcohol solvents having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, butyl alcohol, glycerin propylene glycol and butylene glycol, water and mixtures thereof. The amount of the extraction solvent added to the natural material may be about 1 to 50 times the total volume of the natural material.
본 발명의 한 구체예에서, 천연물 추출용매로 무수 메탄올, 함수 메탄올, 무수 에탄올, 함수에탄올 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매를 사용하는 것이 바람직하다. 또한, 본 발명의 다른 구체 예에서는 상술한 메탄올계 용매 1종 및 상술한 에탄올계 용매 1종의 혼합용매를 사용하는 것이 바람직하다.In one embodiment of the invention, it is preferable to use a solvent selected from the group consisting of anhydrous methanol, hydrous methanol, anhydrous ethanol, hydrous ethanol and mixtures thereof as a natural extractant. In another embodiment of the present invention, it is preferable to use a mixed solvent of one of the aforementioned methanol solvents and one of the aforementioned ethanol solvents.
추출시, 상기 추출용매의 첨가량은 천연물 재료의 건조 중량 1g 당 5~20㎖로 함이 바람직하다. 천연물 재료의 추출 조건은 실온에서 1~7일간 침적 추출하거나 50~95℃의 가온 조건에서 1~5시간 정도 추출하는 방법 등이 사용될 수 있으나 이들로 제한되는 것은 아니며 당 업계에 사용되는 일반적인 용매추출방법이 모두 적용될 수 있다.At the time of extraction, the amount of the extraction solvent added is preferably 5-20 ml per 1 g of the dry weight of the natural product material. Extraction conditions of the natural product material may be used by immersion extraction for 1-7 days at room temperature or 1-5 hours at a heating condition of 50-95 ℃, but is not limited to these general solvent extraction used in the art All of the methods can be applied.
상술한 소나무 잔뿌리, 송이, 잣, 천마 및 오미자로 이루어진 군으로부터 선택되는 2종 이상 혼합물의 추출물을 함유하는 건강식품 조성물의 제형은 특별히 제한되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 본 발명의 건강식품 조성물은 정제, 과립제, 연질캅셀제, 경질캅셀제, 시럽, 음료수, 환(丸), 연조엑스제, 중탕액 등의 제형으로 제조될 수 있다. 보다 구체적으로, 본 발명의 건강식품 조성물은 정제, 과립제, 연질캅셀제, 경질캅셀제, 시럽, 음료수, 환(丸), 연조엑스제, 건조엑스제, 추출중탕액 등의 제형으로 제조될 수 있다. The formulation of the health food composition containing the extract of two or more mixtures selected from the group consisting of pine twigs, pine, pine, cheonma and schizandra mentioned above is not particularly limited and may be appropriately selected as desired. For example, the health food composition of the present invention may be prepared in the form of tablets, granules, soft capsules, hard capsules, syrups, beverages, pills, soft extracts, water baths and the like. More specifically, the health food composition of the present invention may be prepared in the form of tablets, granules, soft capsules, hard capsules, syrups, beverages, pills, soft extracts, dry extracts, extract liquid bath.
또한, 본 발명의 건강식품 조성물은 각각의 제형에 상기 기재한 성분들 이외에 일반 식품의 제조에 배합되는 제형을 위한 부형제, 물, 에탄올, 감미제, 향료, 색소, 방부제 등을 적절히 배합하여 사용할 수 있다.In addition, the health food composition of the present invention can be used by appropriately formulating excipients, water, ethanol, sweeteners, flavorings, pigments, preservatives, and the like for each formulation in addition to the components described above for the formulation of general foods. .
본 발명에 따른 물질을 포함하는 조성물은 치매를 개선하는 건강기능식품을 제공한다. 본 발명에 따른 물질을 포함하는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. 또한, 식품 또는 음료에 첨가될 수 있다. A composition comprising a substance according to the invention provides a dietary supplement that improves dementia. Examples of the food containing the substance according to the present invention include various foods, beverages, gums, teas, vitamin complexes, and health functional foods. It can also be added to food or beverages.
본 발명의 건강식품 조성물은 필수 성분으로서 본 발명에 따른 물질을 함유하는 외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등의 추가 성분을 함유할 수 있다. 상술한 천연 탄수화물의 예로는 모노사카라이드, 예를 들어 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 솔비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제인 타우마틴, 스테비아 추출물, 예를 들어 레바우디오시드 A, 글리시르히진 등; 및 합성 향미제, 예를 들어 사카린, 아스파르탐 등을 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 10 g, 바람직하게는 약 5 내지 6 g이다.
The health food composition of the present invention has no particular limitation on other ingredients besides the substance according to the present invention as an essential ingredient, and may contain additional ingredients such as various flavors or natural carbohydrates, such as ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a flavoring agent other than the above-mentioned, a natural flavoring agent, taumartin, a stevia extract, for example, rebaudioside A, glycyrrhizin, etc .; And synthetic flavoring agents such as saccharin, aspartame and the like. The proportion of such natural carbohydrates is generally about 1 to 10 g, preferably about 5 to 6 g per 100 ml of the composition of the present invention.
이하, 본 발명을 하기 실시예 및 실험예에 의해 더욱 구체적으로 설명한다. 그러나 이들 실시예 및 실험예는 본 발명의 이해를 돕기 위한 것일 뿐, 본 발명의 범위를 제한하고자 하는 것은 아니다.
Hereinafter, the present invention will be described in more detail with reference to the following Examples and Experimental Examples. However, these Examples and Experimental Examples are not intended to limit the scope of the present invention only to aid the understanding of the present invention.
제조예Manufacturing example 1. 혼합 추출물의 제조 1. Preparation of Mixed Extract
소나무 잔뿌리 30 중량 %, 송이 20 중량 %, 잣 20 중량 %, 천마 15 중량 % 및 오미자 15 중량 %를 균일하게 혼합한 혼합물에 80% 에탄올을 혼합물 양의 2배 정도의 부피만큼 가하여 3일간 냉침 시킨 뒤에 용액을 모두 모아 여과지로 여과한 후, 증발기를 이용하여 용매를 제거한 뒤에 동결 건조기에서 건조하여 48시간 이상 건조시켜 분말 상태로 만들었다.
To a mixture of 30% by weight pine root, 20% by weight, 20% by weight pine, 20% by weight, 15% by weight and 15% by weight Schisandra chinensis, 80% ethanol was added to a volume of twice the amount of the mixture and cooled for 3 days. Later, the solution was collected and filtered through filter paper, and then the solvent was removed using an evaporator, dried in a freeze dryer, dried for at least 48 hours, and powdered.
실시예Example 1. 치매 개선용 건강식품의 제조 1. Preparation of health food for improving dementia
하기 표 1의 조성으로 치매 개선용 건강식품을 당업계에 공지된 방법으로 제조하였다. 하기 표 1의 단위는 중량% 이다.
To prepare a health food for improving dementia in the composition of Table 1 below. The units in Table 1 below are by weight.
실시예Example 2. 치매 개선용 건강식품의 제조 2. Preparation of health food for improving dementia
하기 표 1의 조성으로 치매 개선용 건강식품을 당업계에 공지된 방법으로 제조하였다. 하기 표 1의 단위는 중량% 이다.
To prepare a health food for improving dementia in the composition of Table 1 below. The units in Table 1 below are by weight.
비교예Comparative example 1. 치매 개선용 건강식품의 제조 1. Preparation of health food for improving dementia
하기 표 1의 조성으로 치매 개선용 건강식품을 당업계에 공지된 방법으로 제조하였다. 하기 표 1의 단위는 중량% 이다.To prepare a health food for improving dementia in the composition of Table 1 below. The units in Table 1 below are by weight.
실험예Experimental Example 1. 동물 실험 1. Animal Experiment
실험예Experimental Example 1-1.시험액의 제조 1-1.Preparation of Test Solution
소나무 잔뿌리, 송이, 잣, 천마, 오미자 추출물 200mg을 1.0%의 폴리옥시에틸렌 수소화 캐스터오일(Polyoxyethylene hydrogenated castor oil, Cremophor RH 40®,BASF)을 함유하는 생리 식염수 200mg에 가열 용해시켜 화합물 A를 0.1%의 농도로 함유하는 주사 제제를 제조하였다. 시험은 일반적인 건망증 모델을 사용하여 실험을 하였고, 상기 주사 제제를 동물 시험을 통해 기억장해 개선 효과를 확인하였다.200 mg of pine root, pine, pine, cheonma and Schisandra chinensis extracts were dissolved in 200 mg of physiological saline containing 1.0% of polyoxyethylene hydrogenated castor oil (Cremophor RH 40 ® , BASF). Injection formulations containing a concentration of was prepared. The test was carried out using a general forgetfulness model, and the injection preparation was confirmed to have an improvement in memory disorder through animal testing.
실험예Experimental Example 1-2. 실험 동물 준비 1-2. Experimental animal preparation
C57BL/6 수컷 마우스(생후 5~6주)를 준비하였다.
C57BL / 6 male mice (5-6 weeks old) were prepared.
실험예Experimental Example 1-3. 실험 장치 준비 1-3. Experimental Device Preparation
명실(15×10×10cm)과 암실(20×15×12cm)로 이루어진 단계-통과형(step-through type)의 수동적 회피 시험판(자체 제작)을 제작하였다. 명실의 윗부분에서 20-W형광 램프로 명실을 조명하였다. 두 개의 실을 출입구가 위아래로 열고 닫을 수 있는 형태의 출입구로 분리하였다. 이때 암실의 격자를 전기 자극 장치와 연결하여 마우스의 다리에 전기적 쇼크를 줄 수 있도록 하였다.
A step-through type passive avoidance test plate (self-made) consisting of a bright room (15 × 10 × 10 cm) and a dark room (20 × 15 × 12 cm) was produced. At the top of the room, the room is illuminated with a 20-W fluorescent lamp. The two chambers were divided into entrances that could be opened and closed up and down. At this time, the grid of the dark room was connected to the electrical stimulation device to give an electric shock to the leg of the mouse.
실험예Experimental Example 1-4. 충격 시험 1-4. Impact test
마우스를 명실에 넣고, 약 10초 후, 출입구를 열어 마우스가 암실로 들어가도록 하였다. 마우스가 암실로 들어간 직후에 출입구를 닫고, 약 5초 후, AC 45~50V의 전기적 쇼크를 1초간 마우스에 준 후 마우스를 즉시 암실에서 꺼냈다.
The mouse was placed in a clear room and after about 10 seconds the door was opened to allow the mouse to enter the dark room. Immediately after the mouse entered the dark room, the entrance was closed, and after about 5 seconds, an electric shock of AC 45-50V was applied to the mouse for 1 second, and the mouse was immediately taken out of the dark room.
실험예Experimental Example 1-5. 재현 시험 1-5. Reproduction test
충격 시험 24시간 후, 마우스를 다시 명실에 넣고, 전기적 쇼크를 가하지 않은 것을 제외하고는 동일한 방법을 반복하였다. 출입구를 스스로 열고, 마우스가 암실로 들어가기 전까지의 소요 시간(유지기)은 최고 300초로 측정되었다.
After 24 hours of the impact test, the mice were placed back in the clear room and the same procedure was repeated except that no electric shock was applied. The time it takes for the door to open itself and the mouse to enter the dark room is measured up to 300 seconds.
실험예Experimental Example 1-6. 1-6. 전기 경련 쇼크에 의한 건망증 유발Induced forgetfulness by electric spasms shock
충격 시행 직후에, 마우스의 양쪽 귀로 전기 경련 쇼크(AC 100-140V, 0.5초)를 주었다.
Immediately after the impact, both ears of the mouse received an electric spasm shock (AC 100-140 V, 0.5 sec).
실험예Experimental Example 1-7. 시험 화합물의 투여 1-7. Administration of Test Compound
시험 약물은 5개의 군으로 나누어, 음성 대조군과 양성대조군{이데베논(2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadien-1,4-dione)} 및 본 발명에 따른 소나무 잔뿌리, 송이, 잣, 천마 및 오미자로 이루어진 군으로부터 선택된 2종 이상 혼합물의 추출물을 준비하여, 5% 아라비아검을 함유하는 생리 식염수에 현탁시켰다. 준비된 약물을 전기 경련 쇼크에 의한 건망증 유발 시험에서, 재현 시험 30 분전에 화합물을 복강 내 투여하였다.
The test drug was divided into five groups, the negative control group and the positive control group {2- (10-hydroxydecyl) -5,6-dimethoxy-3-methyl-2,5-cyclohexadien-1,4-dione)} and Extracts of two or more mixtures selected from the group consisting of pine twigs, pine, pine, cheonma and schizandra according to the present invention were prepared and suspended in physiological saline containing 5% gum. The prepared drug was administered intraperitoneally 30 minutes before the reproduction test in the forgetfulness-induced test by electroconvulsive shock.
실험예Experimental Example 1-8. 결과 1-8. result
전기 경련 쇼크에 의해 유발된 건망증에 대한 영향 시험 결과를 표 2에 나타내었다. Table 2 shows the results of the effects on forgetfulness caused by electric cramp shock.
평균±S.ERetainer (sec)
Mean ± SE
(Blank)Negative control group
(Blank)
(이데베논)Positive control group
(Idebenon)
* : 전기 경련쇼크 처리 군에 대한 유의차(P<0.05).*: Significant difference (P <0.05) with respect to the electroconvulsive shock treatment group.
(수학식 1)(1)
표 2에서 나타낸 바와 같이, 본 발명의 화합물은 뇌대사 기능 활성제(이데베논) 및 비교예에 비하여 실험적으로 유발된 건망증에 대해 현저한 개선 효과를 나타낸다는 것을 확인하였다.
As shown in Table 2, it was confirmed that the compound of the present invention showed a marked improvement effect on experimentally induced forgetfulness compared to cerebral metabolism activator (idebenone) and the comparative example.
실험예Experimental Example 2. 기억력 개선 임상시험 2. Clinical Trials of Memory Improvement
소나무 잔뿌리, 송이, 잣, 천마 및 오미자로 이루어진 군으로부터 선택된 2종 이상 혼합물의 추출물을 함유하는 치매 개선용 건강식품 조성물의 기억력 향상 효과를 알아보기 위하여 임상 시험을 시행하였다. 대상자는 60세 이상의 노인들을 대상으로 하였으며, 1일 2회 정도 마시도록 하였다. 30명의 대상자를 10명씩 세 그룹으로 나누어 각각 10명씩 상기 실시예 1, 실시예 2, 비교예의 제품을 마시도록 하였다. 실험 제품을 마시는 동안에는 어떠한 치매 관련 치료법(치료요법 혹은 의약품 복용 등)을 금지하도록 조치하였다. 음용 후 그 증상을 평가하도록 하고, 기억력 개선 임상 시험 결과를 하기 표 3에 나타내었다. Clinical trials were conducted to investigate the memory-enhancing effects of dementia-enhancing health food compositions containing extracts of two or more mixtures selected from the group consisting of pine twigs, pine, pine, cheonma and schizandra. The subjects were aged over 60 years old and drink about twice a day. Thirty subjects were divided into three groups of ten people each to drink the products of Example 1, Example 2, and Comparative Example. While drinking the experimental product, it was decided to prohibit any dementia-related treatments (such as therapy or medication). The symptom was evaluated after drinking, and the results of the clinical trial for improving memory are shown in Table 3 below.
상기 표 3의 결과로부터, 본 발명의 치매 개선용 건강식품 조성물은 기억력을 향상시켜 치매를 개선하는데 도움이 된다는 것을 알 수 있었다.
From the results of Table 3, it was found that the health food composition for improving dementia of the present invention is helpful in improving dementia by improving memory.
지금까지 예시적인 실시 태양을 참조하여 본 발명을 기술하여 왔지만, 본 발명의 속하는 기술 분야의 당업자는 본 발명의 범주를 벗어나지 않고서도 다양한 변화를 실시할 수 있으며 그의 요소들을 등가물로 대체할 수 있음을 알 수 있을 것이다. 또한, 본 발명의 본질적인 범주를 벗어나지 않고서도 많은 변형을 실시하여 특정 상황 및 재료를 본 발명의 교시내용에 채용할 수 있다. 따라서, 본 발명이 본 발명을 실시하는데 계획된 최상의 양식으로서 개시된 특정 실시 태양으로 국한되는 것이 아니며, 본 발명이 첨부된 특허청구의 범위에 속하는 모든 실시 태양을 포함하는 것으로 해석되어야 한다.
While the present invention has been described with reference to exemplary embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. You will know. In addition, many modifications may be made to adapt a particular situation and material to the teachings of the invention without departing from the essential scope thereof. Accordingly, it is intended that the invention not be limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but that the invention be construed as including all embodiments falling within the scope of the appended claims.
Claims (7)
상기 혼합물의 추출물이 조성물 총 중량에 대하여 각각 0.001~10 중량%의 양으로 함유되는 것을 특징으로 하는 치매 개선용 건강식품 조성물.The method of claim 1,
Extract of the mixture is dementia improvement health food composition, characterized in that it is contained in an amount of 0.001 to 10% by weight relative to the total weight of the composition.
상기 혼합물의 조성이 건조중량을 기준으로 하여 소나무 잔뿌리 1 ~ 40 중량%, 잣 1 ~ 40 중량%, 천마 1 ~ 40 중량% 또는 오미자 1 ~ 40 중량%의 양으로 함유되는 것을 특징으로 하는 치매 개선용 건강식품 조성물.The method of claim 1,
Improvement of dementia, characterized in that the composition of the mixture is contained in an amount of 1 ~ 40% by weight, pine tree 1-40% by weight, 1-40% by weight, 1-40% by weight or Schisandra chinensis based on dry weight Health food composition for.
상기 건강식품 조성물이 정제, 과립제, 연질캅셀제, 경질캅셀제, 시럽, 음료수, 환(丸), 연조엑스제, 건조엑스제, 중탕액 및 추출중탕액으로 이루어진 군으로부터 선택되는 1종 이상의 제형인 것을 특징으로 하는 치매 개선용 건강식품 조성물.The method of claim 1,
The health food composition is one or more formulations selected from the group consisting of tablets, granules, soft capsules, hard capsules, syrups, beverages, pills, soft extracts, dry extracts, water baths and extract baths Health food composition for improving dementia.
상기 추출물이 물, 유기용매 또는 이들의 혼합물로 추출되는 것을 특징으로 하는 치매 개선용 건강식품 조성물.The method of claim 1,
Dementia improvement health food composition, characterized in that the extract is extracted with water, an organic solvent or a mixture thereof.
상기 유기용매가 탄소수 1 내지 4의 알코올성 용매인 것을 특징으로 하는 치매 개선용 건강식품 조성물.The method of claim 5, wherein
Dementia improvement health food composition, characterized in that the organic solvent is an alcoholic solvent having 1 to 4 carbon atoms.
상기 유기용매가 메탄올, 에탄올, 프로필 알코올, 부틸알코올, 글리세린 프로필렌글라이콜 및 부틸렌글라이콜로 이루어진 군으로부터 선택되는 1종 이상인 것을 특징으로 하는 치매 개선용 건강식품 조성물. The method according to claim 6,
The organic solvent is a health food composition for improving dementia, characterized in that at least one selected from the group consisting of methanol, ethanol, propyl alcohol, butyl alcohol, glycerin propylene glycol and butylene glycol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110092638A KR20130029284A (en) | 2011-09-14 | 2011-09-14 | Composition of healthy foods for treatment of dementia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110092638A KR20130029284A (en) | 2011-09-14 | 2011-09-14 | Composition of healthy foods for treatment of dementia |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130029284A true KR20130029284A (en) | 2013-03-22 |
Family
ID=48179284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110092638A KR20130029284A (en) | 2011-09-14 | 2011-09-14 | Composition of healthy foods for treatment of dementia |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130029284A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210010759A (en) | 2019-07-19 | 2021-01-28 | 주식회사 퓨톤 | Pharmaceutical and health food composition cerebrovascular for improving cognitive disorder containing extraction of cone of Korean pine |
WO2022215764A1 (en) * | 2021-04-06 | 2022-10-13 | 주식회사 에스알파테라퓨틱스 | Digital apparatus and application for treatment of mild cognitive impairment and dementia |
KR20230105366A (en) | 2022-01-04 | 2023-07-11 | 호서대학교 산학협력단 | Composition for treating neurodegenerative diseases comprising essential oil derived from pine cones |
US11903721B1 (en) | 2019-12-31 | 2024-02-20 | S-Alpha Therapeutics, Inc. | Digital apparatus and application for treating mild cognitive impairment and dementia |
-
2011
- 2011-09-14 KR KR1020110092638A patent/KR20130029284A/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210010759A (en) | 2019-07-19 | 2021-01-28 | 주식회사 퓨톤 | Pharmaceutical and health food composition cerebrovascular for improving cognitive disorder containing extraction of cone of Korean pine |
US11903721B1 (en) | 2019-12-31 | 2024-02-20 | S-Alpha Therapeutics, Inc. | Digital apparatus and application for treating mild cognitive impairment and dementia |
WO2022215764A1 (en) * | 2021-04-06 | 2022-10-13 | 주식회사 에스알파테라퓨틱스 | Digital apparatus and application for treatment of mild cognitive impairment and dementia |
KR20230105366A (en) | 2022-01-04 | 2023-07-11 | 호서대학교 산학협력단 | Composition for treating neurodegenerative diseases comprising essential oil derived from pine cones |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
KR101498780B1 (en) | Composition for preventing or treating hangover | |
US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
KR101789424B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine Proving Insomniac and the Method of Making the Same | |
WO2016099043A1 (en) | Drink composition for hangover relief and liver function improvement | |
KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
CN106616183B (en) | Solid beverage composition with maca and dandelion as main flavor agents and preparation method thereof | |
KR101826737B1 (en) | A composition containing herbs extract, and manufacturing method of the same | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR101483255B1 (en) | Korean Herb Tea composing of extract from Spring onion root and Method preparing thereof | |
KR20130029284A (en) | Composition of healthy foods for treatment of dementia | |
KR20120131337A (en) | A functional beverage composition of extract of Artemisia iwayomogi, extract of Hovenia dulcis, extract of Taraxacum mongolicum, extract of Jujube, extract of Pueraria lobata and extract of Acanthopanax sessiliflorum as main ingredients | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR101179766B1 (en) | enhance learning ability health food | |
KR100891914B1 (en) | The method of preparing the functional food for diet using extrative extrated from madicin-matrrials of plants | |
CN105029553A (en) | Fruit juice-egg-calcium traditional Chinese medicine health beverage and preparation method thereof | |
CN111567797A (en) | Compound jasmine tea chewable tablet and preparation method thereof | |
KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
KR102229547B1 (en) | A composition for improving, preventing and treating of liver diseases comprising Milk thistle and Taraxacum platycarpum Dahlst | |
KR100638491B1 (en) | Compounds for relief of alcoholic hangover and drug containing the compounds | |
KR101999675B1 (en) | Herbal composition for the prevention and treatment of coronary heart disease | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR101221623B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of root of vitis | |
KR100761552B1 (en) | Herbextract for removing harmful elements caused by smoking and manufacturing method of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |